We are assembling an outstanding team of biomedical, material and computer scientists, mechanical, chemical and electrical engineers and tool builders with expertise ranging from biology, genetics, chemistry, machine learning, informatics, drug development and medicine. In the pursuit of our mission, we are entering into collaborations and partnerships with some of the most prominent academic institutions and biotechnology companies.

Our current technology development is in collaboration with Anil Narasimha’s Lab at Stanford Center for Genomics and Personalized Medicine, Bianxiao Cui’s Lab at Stanford ChemistryStanford Institute for Stem Cell Biology and Regenerative Medicine, Lawrence Berkeley National Laboratory and QB3 Berkeley Biomolecular Nanotechnology Center. We are also in talks with other institutions for possible collaborative R&D. We are primarily interested in partnerships with biotech companies based around single cell deep sequencing capabilities and analyses such as transcriptomics, proteomics and metabolomics, machine learning for computational biology for integration into our nano-robotic system, microscopy/imaging and micro optics array.

Our interdisciplinary collaboration with Stanford University has given us outstanding access to strong robotic capabilities for automated sample manipulation, sequencers, oligonucleotide synthesizers, computational servers, state-of-the-art Class 100 cleanroom fabrication, nanocharacterization lab, imaging facilities, core flow cytommetry facility, viral production core, human iPS and ES cell core facilities.


Mekonos is essentially a nanorobotics company that is leveraging on the advances made in nanoscale engineering and genetics to tackle cell therapy at a clinical scale. That is our primary focus. Toward that goal, we are also developing single cell manipulation platforms that will help the research community toward drug development (target identification and high throughput screening), toxicology and functional genomics. Our key biological areas of interest include ex vivo gene transfer and therapy, engineering T cells to co-ordinate immunity, use of CRISPR-Car systems for genome editing and single-cell DNA and RNA sequencing. Our key engineering areas of interest include micromachining and characterization, control architecture development, image processing, machine learning and micro optics.


Mekonos is flexible regarding our collaboration and partnerships model. As such, they can range from sponsored research with leading academic investigators to licensing agreements with biotechnology companies for clinical-level drug discovery and therapeutic development programs. If you would like to collaborate or partner with Mekonos, please email us a non-confidential proposal to kiwee[at]mekonos[dot]com

 Copyright (c)2016 Mekonos Limited Inc. All rights reserved.